Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ford

Showing results (1201-1210 of 1,228) with videos related to

Pageof 123
Sort By:
Cancer Research|April 29, 2020
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and MetastasisHengbo Zhou, Melanie A Blevins, Jessica Y Hsu, et al.
JAMA Network Open|July 22, 2024
Changes in Emergency Department Pediatric Readiness and MortalityCraig D Newgard, Shauna Rakshe, Apoorva Salvi, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
Science (New York, N.Y.)|November 6, 2020
Past climates inform our futureJessica E Tierney, Christopher J Poulsen, Isabel P Montañez, et al.
Scientific Data|December 6, 2022
The PhanSST global database of Phanerozoic sea surface temperature proxy dataEmily J Judd, Jessica E Tierney, Brian T Huber, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
Nature Microbiology|August 7, 2023
Vertical and horizontal gene transfer shaped plant colonization and biomass degradation in the fungal genus ArmillariaNeha Sahu, Boris Indic, Johanna Wong-Bajracharya, et al.
Pageof 123

Showing results (1201-1210 of 1,228) with videos related to

Sort By:
Pageof 123
Cancer Research|April 29, 2020
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and MetastasisHengbo Zhou, Melanie A Blevins, Jessica Y Hsu, et al.
JAMA Network Open|July 22, 2024
Changes in Emergency Department Pediatric Readiness and MortalityCraig D Newgard, Shauna Rakshe, Apoorva Salvi, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
Science (New York, N.Y.)|November 6, 2020
Past climates inform our futureJessica E Tierney, Christopher J Poulsen, Isabel P Montañez, et al.
Scientific Data|December 6, 2022
The PhanSST global database of Phanerozoic sea surface temperature proxy dataEmily J Judd, Jessica E Tierney, Brian T Huber, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
Nature Microbiology|August 7, 2023
Vertical and horizontal gene transfer shaped plant colonization and biomass degradation in the fungal genus ArmillariaNeha Sahu, Boris Indic, Johanna Wong-Bajracharya, et al.
Pageof 123